Reveris Therapeutics

A pre-clinical stage pharmaceutical company developing novel therapeutics for triple negative breast cancer.

  • Company Overview
  • The Team
  • Our Approach
  • Contact Us

Company Overview

About Reveris

Reveris Therapeutics is a pre-clinical stage pharmaceutical company developing novel therapeutics for triple negative breast cancer (TNBC). More than 34,500 women are diagnosed with TNBC in the United States each year, yet no targeted therapy currently exists for TNBC.

Reveris Therapeutics aims to develop highly efficacious, nontoxic small molecule inhibitors to treat TNBC. Our unique approach selectively targets and kills susceptible cancer cells, but not normal cells, promising improved efficacy and fewer side effects for patients. Reveris’ established team, network of collaborators and singular focus is enabling Reveris to advance our pioneering technology toward the clinic.

Meet the Team →

NEWS

September 2018

The NCI awarded Reveris Therapeautics a 1 year STTR supplement.

June 2017

Notice of award: Biotechnology Innovation Grant from the North Carolina Biotechology Center, “Developing Small Molecule Inhibitors of CIB1”.

February 2017

Dale Christensen PhD, joins Reveris as CSO

January 2016

Reveris receives One NC Small Business Matching Grant

September 2015

Reveris receives STTR from NCI, “Developing therapeutic inhibitors of CIB1 for Breast Cancer”

August 2015

Reveris receives Carolina Kickstart Commercial Collaboration award

November 2014

Parise lab awarded Technology Development Grant from UNC’s Office of Technology Development

November 2014

Parise lab wins Drugs, Devices and Diagnostic Development Award (4D)  from NC TraCS

Copyright © 2019 REVERIS THERAPEUTICS · Log in · A Ruby Red Site